Academisch Ziekenhuis Maastricht

Maastricht UMC+ Develops Promising Drug for Hereditary Fructose Intolerance Treatment

- Researchers at Maastricht UMC+ have successfully tested a novel drug that blocks toxin accumulation in patients with hereditary fructose intolerance, potentially eliminating the need for strict dietary restrictions. - Clinical trials with three patients demonstrated successful fructose excretion through urine without triggering symptoms, marking a significant breakthrough for the rare metabolic disorder. - The development offers hope to approximately 200 patients in the Netherlands with hereditary fructose intolerance, who currently must maintain strict fructose-free diets to avoid severe health complications.